MFAR
13
6
6
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
15.4%
2 terminated/withdrawn out of 13 trials
71.4%
-15.1% vs industry average
8%
1 trials in Phase 3/4
80%
4 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.
Role: collaborator
Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial
Role: collaborator
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
Role: collaborator
Retrospective Analysis of the Experience With Larotrectinib in Patients With Solid Neoplasms With NTRK Fusion in Spain (SPAINTRK)
Role: collaborator
Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.
Role: collaborator
Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases
Role: collaborator
CEB-01 in Locally Resectable Pancreatic Cancer
Role: collaborator
Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain
Role: collaborator
Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma
Role: collaborator
Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach
Role: collaborator
Sacituzumab govitEcan in THYroid Cancers
Role: collaborator
E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C
Role: collaborator
Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma
Role: collaborator
All 13 trials loaded